Safety and clinical activity of durvalumab combined with tremelimumab in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase I study

Programmed cell death protein 1 (PD-1) inhibitors prolong survival versus chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC), which often expresses cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death-ligand 1 (PD-L1), providing a rationa...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	ESMO open 2024-08, Vol.9 (8), p.103646, Article 103646
Hauptverfasser:	Algazi, A., Papadopoulos, K.P., Tsai, F., Hansen, A.R., Angra, N., Das, M., Sheth, S., Siu, L.L.
Format:	Artikel
Sprache:	eng
Schlagworte:	CTLA-4 inhibitor head and neck squamous cell carcinoma immunotherapy Original Research PD-L1 inhibitor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!